AG
LAB icon

Aperio Group’s Standard BioTools LAB Stock Holding History

Aperio Group’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-10,698
Closed -$43K – 2387
2020
Q2 		$43K Buy
10,698
+119
+1% +$414 ﹤0.01% 2304
2020
Q1 		$27K Buy
+10,579
New +$34.8K ﹤0.01% 2299
2019
Q3 		– Sell
-10,044
Closed -$124K – 2544
2019
Q2 		$124K Buy
+10,044
New +$128K ﹤0.01% 2320

Other funds holding LAB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Atom Investors Austin, Texas $1.4B AUM 23.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Aperio Group's LAB Position: Q3 2020 in Review

Aperio Group sold out of Standard BioTools (LAB) in Q3 2020, closing a stake of 10,698 shares — an estimated $43K sold.

Aperio Group first reported a position in LAB in Q2 2019 and held it in 3 quarters. The position peaked at $124K in Q2 2019. 134 funds tracked by Wall St. Rank hold LAB as of Q3 2020.

  • Aperio Group reported no remaining Standard BioTools position as of Q3 2020 after selling out during the quarter.
  • Aperio Group sold 10,698 Standard BioTools shares in Q3 2020, an estimated $43K.
  • Aperio Group first reported a position in Standard BioTools in Q2 2019 and held it in 3 quarters.
  • Aperio Group's Standard BioTools position peaked at $124K in Q2 2019.
  • 134 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2020.

Based on Aperio Group's 13F filing for Q3 2020, filed 6 Nov 2020.